Dalpiciclib combined with pyrotinib and endocrine therapy in women with ER-positive, HER2-positive advanced breast cancer: A prospective, multicenter, single-arm, phase 2 trial.

Dalpiciclib combined with pyrotinib and endocrine therapy in women with ER-positive, HER2-positive advanced breast cancer: A prospective, multicenter, single-arm, phase 2 trial.

Show other versions (1)

<h4>Background</h4>Combination of HER2-targeted therapy and endocrine therapy offers a more tolerable alternative to HER2-targeted chemotherapy regimens for estrogen receptor (ER)-positive, HER2-positive advanced breast cancer (ABC), but with compromised efficacy. The addition of cyclin-...

Full description

Saved in:
Bibliographic Details
Main Authors: Jian Zhang, Yanchun Meng, Biyun Wang, Xinhong Wu, Hongmei Zheng, Jing Hu, Wei Liu, Wenyan Chen, Leiping Wang, Jun Cao, Zhonghua Tao, Ting Li, Sujie Ni, Zhengyan Yu, Lichun Sun, Yun Wang, Qiang Peng, Song Wang, Xin Hu, Jianfei Wang, Yijia Wu, Xichun Hu
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2025-07-01
Series:PLoS Medicine
Online Access:https://doi.org/10.1371/journal.pmed.1004669
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1371/journal.pmed.1004669

Similar Items